Merck & Co., Inc.'s first quarter 2011 earnings call presented several positive indicators that suggest a strong short-term outlook for the company. Here are the key points:

- **Strong Financial Performance**: Merck reported strong revenues and double-digit EPS growth, driven by the performance of key products such as JANUVIA, JANUMET, SINGULAIR, REMICADE, and ISENTRESS. The company maintained its top-line target for 2011 and raised the midpoint of its non-GAAP EPS guidance range despite facing headwinds like generic erosion and health care reform[5|.
- **Cost Control and Efficiency**: Merck achieved significant cost reductions across various expense categories, including marketing, administrative, and R&D expenses. This demonstrates the company's commitment to financial discipline and efficiency[5|.
- **Pipeline Progress**: The company highlighted multiple approvals and positive developments in its late-stage pipeline, including the upcoming launch of VICTRELIS for hepatitis C treatment and other promising candidates like SYLATRON and anacetrapib[5|.
- **Strategic Initiatives**: Merck's joint venture with Sun Pharma and the acquisition of Inspire Pharmaceuticals are strategic moves aimed at expanding its presence in emerging markets and enhancing its product portfolio[5|.
- **Shareholder Value**: The company announced a $5 billion stock buyback program, reflecting its confidence in the business and commitment to returning value to shareholders[5].

Given these positive factors, the stock is likely to experience a positive impact in the short term.

**Rating: 1**